We are

We areUnique

We are a leading science and technology company, active in Healthcare, Life Science and Performance Materials. Since our establishment 350 years ago in Darmstadt, Germany, we have become truly global. Today, our more than 52,000 employees working on breakthrough solutions and technologies in 66 countries.

We are known as ”Merck” internationally except for the United States and Canada, where we operate as EMD Serono in the biopharmaceutical business, MilliporeSigma in the life science business, and EMD Performance Materials in the high-tech materials business.

cuRIosITYCelebrating 350 years of

We work to achieve progress for patients, customers and society as a whole. Our global network of scientists, experts and thought leaders is driven by the passion to explore and the prospect of making a meaningful difference in the world.As a leading science and technology company, we discover and develop for life in all its vibrancy, drawing on our unique expertise in healthcare, life science and performance materials. Our ideas are everywhere, from cancer therapies and laboratory tools to the display of your smartphone or the color of your car.

Curiosity has been our driving force since 1668. That’s why our anniversary year in 2018 revolves not only around our past. It centers on the future. Today more than ever, a changing world drives us to explore, innovate and collaborate with others in search of tomorrow’s technologies.

So, join us in celebrating 350 years of curiosity. It’s the power that connects us as partners, drives human progress and challenges us to imagine the next 350 years.

Stefan Oschmann Chairman of the Executive Board and CEO

It is in our DNA to search for answers to some of the most pressing questions of the future.The growing world population and a general increase in life expectancy are dramatically changing our society and the way we live. So are the scarcity of resources, sustainable connected mobility as well as the Internet of Things and digitalization. These changes are driving the demand for sustainable, personalized and connected products, including new technologies and services in the healthcare, life science and performance materials industries.

Our more than 6,500 R&D professionals worldwide are dedicated to discovering and developing pioneering solutions and technologies, such as genome editing and deep data analysis. Their efforts are helping to accelerate and improve drug development and biomedical technologies and leading to innovations such as sensor systems, and ever smaller, and highly efficient microchips for the next generation of technical devices.

Human PRoGRess

Curious minds dedicated to

GRounD BReaKING

Discoveries

H E A LT H C A R E

In Healthcare, patients are at the center of everything we do.Our research and development (R&D) focus on patients whose needs are still unmet. We invest substantial amounts in developing new therapies and medical technologies – for instance against cancer and chronic progressive diseases, especially those of the immune system, including multiple sclerosis (MS). At our R&D hubs in Darmstadt, Boston, Beijing, and Tokyo, around 3,000 employees work in global networks, aiming to make groundbreaking discoveries for the benefit of patients.

We also collaborate with external partners – including renowned data specialists. In the fight against cancer and other serious diseases, sophisticated data analytics will be a powerful weapon. They will help us to identify meaningful patterns – for example, how the immune system of specific patient groups interacts with specific illnesses – and develop personalized treatments.

Worldwide, some 2.3 million people have multiple sclerosis (MS), a chronic disease of the central nervous system.

Significant progress has been made in MS care over the past few decades. However, there is still potential for further improvements, both in treatment choices and patient support. For more than two decades, we have been dedicated to advancing care in MS and to conducting research in the field of immunology.

An estimated 14 million people across the globe are diagnosed with cancer every year – a number that is expected to increase significantly over the next decade due to growing world population and increasing life expectancy.

Immuno-oncology therapies have the potential to bring great improvements for many cancer patients. They harness the immune system to attack tumors more efficiently. Given our ambition to develop breakthrough therapies for cancer, we conduct comprehensive research and development and are working on several R&D projects in this field.

For some couples, the wish to have a baby leads to a long and difficult personal and medical journey:

Nine percent of couples around the world struggle to conceive. Building on our fertility expertise that goes back to 1906, we have continuously generated innovation in this area. Today, we are a global market leader in the field of fertility treatments. An estimated 2.5 million babies worldwide have been born with the help of our products. We are complementing our drug portfolio with a continually growing number of fertility technologies, aiming to further increase the chances of treatment success.

Our portfolio addresses therapeutic areas such as:

Oncology & Immuno-Oncology (e.g. cancer)

Neurology & Immunology (e.g. multiple sclerosis)

Fertility

Endocrinology (e.g. growth hormone disorders)

General Medicine (e.g. thyroid, type 2 diabetes

and cardiovascular diseases)

Allergies

H E A LT H C A R E

Our aim in Life Science is to accelerate access to health for people everywhere. To that end, we collaborate with the global scientific community and offer high-quality products and solutions both for research and the manufacturing of chemical and biological drugs. We also provide products and solutions for diagnostics, environmental testing and industrial customers.

We help scientists and engineers to solve problems at every stage of their work. Our lab materials, technologies and services help make research, pharmaceutical and biotech production simpler, faster and safer. They enable scientific discovery by helping customers better understand biological function and disease.

L I F E S C I E N C E

woRLD cLass PaRTneR

Since the human genome was fully decoded 15 years ago, much has happened in medical research and biotechnology.

With CRISPR genome editing technology, for example, the DNA of an organism can be “edited”. Certain gene sequences can be separated or “cut” and replaced in a cell. This allows scientists to understand the link between a gene and its function in the cell, and to alter DNA of plants, animals and humans in a targeted manner, for instance to help make plants that are more drought resistant or fight diseases.

Our genome editing products help scientists make these life changing possibilities a reality.These possibilities are also coupled with enormous responsibility. We conduct genome editing research in compliance with statutory regulations and careful consideration of ethical standards and a clearly defined ethics policy.

The aging population, an increase in chronic diseases and the potential of personalized medicine are driving the demand for drug manufacturers to innovate their development and manufacturing processes to get therapies to patients more quickly, cost effectively and safely.

Biological treatments, such as gene therapy that are manufactured in a microorganism, plant or animal cells, have great potential in treating illnesses where there is currently no other treatment available. At the same time, the clinical development journey of a new biologic is a long and challenging process. We collaborate with pharma and biopharma manufacturers to develop and formulate their drugs, as well as evaluate their safety.

By helping our partners create a more modern, scalable, manufacturing process, we aspire to accelerate access to life-saving new therapies to address the healthcare needs of low- and middle-income countries.

The safety of our food is something we often take for granted. Luckily, our customers in the food manufacturing industry don’t.

A comprehensive portfolio, combined with our regulatory expertise, enables them to quickly test for a wide variety of pathogens – harmful microorganisms such as Salmonella or Listeria.

Microorganisms pose a severe threat to the consumer products we interact with daily. If particles end up in the air, on surfaces, and in water, fuel and other liquids, the consequences can be serious for human health and safety, as well as for process efficiency. We offer customers a variety of products for air testing, which provide the most reliable protection against particle contamination.

We provide state-of-the art tools, technologies and services in fields such as:

Clinical & Diagnostics

Emerging Biotech (new biotechnology companies)

Environmental Testing

Food & Beverage

Government & Academic Research

Industrial (manufacturing and distribution)

Pharma & Biopharma Manufacturing

Pharmaceutical Research

Pharma Quality Control

L I F E S C I E N C E

Through our Performance Materials business, we offer specialty chemicals that enrich people’s lives in many ways.Be it the liquid crystals or OLED materials in the display of your smartphone, the effect pigments in the coating of your car or the high-performance materials that make the microchips in your electronic devices possible, it is likely that you have come into contact with our products today.

P E R F O R M A N C E M AT E R I A L S

maKInG LIFe RIcHeR

We offer specialty chemicals and solutions for surfaces,

displays and semiconductors for the following industries,

among others:

Electronics & Technology

Cosmetics

Lighting & Solar

Architecture

Automotive

Food & Beverage

From connectivity and eco-friendliness through to cutting-edge design, we address the need for new technological materials for future mobility.

The automotive solutions we are developing range from display and lighting materials to liquid crystal antennas with particularly high data transmission speeds – a prerequisite for autonomous driving. Further examples are high-tech materials for sensors, liquid crystal window technology that allows car windows and sunroofs to be darkened individually at the push of a button, or effect pigments for exterior coatings.

Our technologies enable smart devices.

In your smartphone, for example, semiconductors like fingerprint sensors, memory chips, processors, Wi-Fi modules or even the camera couldn’t be produced without our specialty chemicals. While our OLED and liquid crystal technologies make the images displayed on your phone sharper, our semiconductor materials make it faster and smarter and our effect pigments create a more durable, scratch-resistant surface for the shell of your phone.

Our liquid crystal and OLED display solutions create sharper images on the displays of more than half of the world’s flat-screen televisions, tablet computers and smartphones.

Always thinking beyond current technologies, we are researching and developing the next generation of materials for lighting and displays. OLED (organic light-emitting diode) materials, for instance, are ideal for the flexible and curved displays of the future. They transform surfaces into a brilliant display with just one swipe and provide brilliant colors and sharp images from every viewing angle. What’s more, they are extremely energy-efficient. The many uses for OLEDs include cars, where they can power internal and external lighting, as well as interior, free-form displays.

P E R F O R M A N C E M AT E R I A L S

K E Y F I G U R E S

15,327 2017

15,024 2016

12,845 2015

11,363 2014

10,735 2013

Sales 2013-2017 ( € million )

Key figures ( € billion )

2017 sales by business sector ( € million )

Employees Worldwide

As of December 31, 2017Sales 15.0 15.3

EBITDA pre 4.5 4.4

Margin (% of sales) 29.9 28.8

R&D costs 2.0 2.1

Business free cash flow 3.3 3.3

Employees (on Dec. 31) 50,414 52,941

Healthcare (46%)

6,999 Life Science (38%)

5,882 Performance

Materials (16%)

2,446

Europe (31%)

4,756 Asia-Pacific (32%)

4,921 Middle East & Africa (4%)

608North America (25%)

3,810Latin America (8%)

1,232

2017 sales by region

( € million )

2017 EBITDA pre by business sector ( € million )

Healthcare (41%)

1,949Life Science (38%)

1,786 Performance Materials (21%)

980

A company history of 350 years speaks for itself. Respecting the interests of our employees, customers, owners and society is the key to a successful future.Our anniversary year in 2018 is a special opportunity to strengthen our role as corporate citizen. To mark our anniversary we will conduct 350 good deeds throughout the world with a special focus on the communities where our employees live and work.

In terms of our long-term corporate responsibility strategy, we focus on those areas where we can make the greatest impact.

R E S P O N S I B I L I T Y

SUCCESSFUL BusIness ConSCIenCewith a

Furthermore, we provide the key active component in flexible organic photovoltaics (OPV) for the cost-effective production of resource-conserving and flexible solar panels. The extremely lightweight organic solar foils can be used on all kinds of surfaces, inspiring architects to design smart buildings with energy-generating facades.

Education & Culture

We believe that culture inspires people, opening minds to new possibilities and fueling creativity. Our company philharmonic orchestra is our musical ambassador. Furthermore, we support and implement literature and educational projects, such as junior labs and scholarships, with an emphasis on science education for children and teens. In 2017, we launched the Curiosity Cube™, a retrofitted shipping container transformed into a mobile science lab that traveled throughout the U.S. sparking curiosity in students through free, hands-on science experiments.

R E S P O N S I B I L I T Y

Health

Our initiatives, programs and partnerships particularly address unmet medical needs in low and middle-income countries, with a special focus on schistosomiasis. Together with the World Health Organization (WHO) and other partners, we are working to eliminate the parasitic worm disease. We also regularly conduct awareness campaigns globally for conditions such as diabetes, thyroid disorders or cancer, as well as research activities related to infectious diseases include malaria, bacterial infections, and antimicrobial resistance.

Environment

We continuously work to reduce our own ecological footprint. In doing so, we also help our customers achieve their own sustainability goals. The development of new liquid crystal technologies or organic light-emitting diodes (OLED) for example, reduce the energy consumption of smartphones, tablets or TVs.

Points of Pride

700 million praziquantel tablets have been donated

since 2007 to battle schistosomiasis

€ 200 million has been invested in environmental protection,

health and safety efforts in 2017

€ 15 million has been invested in our new Netherlands facility

to produce energy-efficient liquid crystal window modules

38,040 students visited the Curiosity Cube™ mobile science

lab in the United States in 2017

3 5 0 Y E A R S O F C U R I O S I T Y

Science has been a pillar of our business since the age of Enlightenment.Since 1827, we have been pioneers in research driven industries, setting technology and quality standards.

These strong roots have driven our growth and passion for discovery to this very day.

2017

Regulatory approvals for

drugs in the therapeutic

areas of cancer and chronic

progressive diseases of

the immune system

1827

Emanuel Merck drives the transformation from a pharmacy

craft to a research-based industrial company forward with the presentation

of the “Cabinet of Pharmaceutical and Chemical Innovations”

19 0 4

Start of liquid crystal research

19 67

Launch of the Super-Q® Water Purification system, simplifying the conversion of tap water to ultra-pure

water for laboratories

19 87

Immunology research starts with a focus on cancer therapy

2018

350th anniversary with the theme:

Always curious – Imagine the next 350 years

Opening of our new Innovation Center at our

headquarters in Darmstadt

2010

Acquisition of Millipore, making us a leading global partner for the life science industry

20 03

Entry into targeted cancer therapies

19 9 0

Diabetes becomes a therapeutic area

16 6 8

Friedrich Jacob Merck lays the foundation for our company

20 07

Acquisition of Serono, transforming us into a

leading biotech company

Since 1668, we have developed from a small pharmacy into a leading science and technology company.

350 years later, the founding family is still our majority owner.Thinking in generations – not just in quarters – has allowed us to invest in diversified businesses.

2015

Acquisition of Sigma-Aldrich, expanding

our leading position in the life science business

EMDgroup.com

Merck KGaA, Darmstadt, Germany – Who we are Published in April 2018 Group Communications Frankfurter Strasse 250 64293 Darmstadt, Germany

+ 49 6151-72-0 comms@emdgroup.com